In a report released today, Gbola Amusa from Chardan Capital maintained a Buy rating on Nightstar Therapeutics Limited (NASDAQ: NITE), with a price target of $40. The company’s shares opened today at $14.01.
According to TipRanks.com, Amusa is a 5-star analyst with an average return of 25.1% and a 53.8% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Arbutus Biopharma Corporation, and Applied Genetic Technologies.
Nightstar Therapeutics Limited has an analyst consensus of Moderate Buy, with a price target consensus of $30.
See today’s analyst top recommended stocks >>
The company has a one-year high of $24.94 and a one-year low of $10.01. Currently, Nightstar Therapeutics Limited has an average volume of 17.13K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nightstar Therapeutics PLC is a clinical-stage gene therapy company, which engages in the development and commercialization of novel one-time treatments for patients suffering from rare inherited retinal diseases. Its pipeline includes NSR-REP1, for the treatment of choroideremia; NSR-RPGR, for the treatment of X-linked retinitis pigmentosa; and NSR-BEST1, for the treatment of vitelliform macular dystrophy. The company was founded by Robert MacLaren on July 6, 2017 and is headquartered in London, the United Kingdom.
